Evidence map›Paper›PMID 12941891›Full record

ArticleJournal of virology2003

Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

Sang-Moo Kang, Qizhi Yao, Lizheng Guo, Richard W Compans

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Virus-like particles: models for assembly studies and foreign epitope carriers.Progress in nucleic acid research and molecular biology · 2005
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sang-Moo KangDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Qizhi Yao
Lizheng Guo
Richard W Compans
Emory University · USBaylor College of Medicine · US

Funding

Novel VLP-Based Mucosal and Sytemic HIV VaccinesU19AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 2003 to 2009
$15.8M
PROTEIN IMMUNOGENSP01AI043045 · NIAID · EMORY UNIVERSITY · PI ROBINSON, HARRIET L · 1998 to 2003
$5.6M
POLIOVIRUS REPLICONS FOR HIV/SIV VACCINESP01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MORROW, CASEY D · 1998 to 2002
$5.1M
RECOMBINANT VACCINES DERIVED FROM POLIOVIRUSU01AI028147 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FULTZ, PATRICIA N · 1989 to 1997
–
NIAID NIH HHS AI 28147NIAID NIH HHS AI 43045NIAID NIH HHS P01 AI028147NIAID NIH HHS P01 AI043045NIAID NIH HHS U01 AI028147NIAID NIH HHS U19 AI028147
6 · The paper itself

Abstract

To enhance the efficiency of antigen uptake at mucosal surfaces, CTB was conjugated to simian immunodeficiency virus (SIV) virus-like particles (VLPs). We characterized the immune responses to the Env and Gag proteins after intranasal administration. Intranasal immunization with a mixture of VLPs and CTB as an adjuvant elicited higher levels of SIV gp160-specific immunoglobulin G (IgG) in sera and IgA in mucosae, including saliva, vaginal-wash samples, lung, and intestine, as well as a higher level of neutralization activities than immunization with VLPs alone. Conjugation of CTB to VLPs also enhanced the SIV VLP-specific antibodies in sera and in mucosae to similar levels. Interestingly, CTB-conjugated VLPs showed higher levels of cytokine (gamma interferon)-producing splenocytes and cytotoxic-T-lymphocyte activities of immune cells than VLPs plus CTB, as well as an increased level of both IgG1 and IgG2a serum antibodies, which indicates enhancement of both Th1- and Th2-type cellular immune responses. These results demonstrate that CTB can be an effective mucosal adjuvant in the context of VLPs to induce enhanced humoral, as well as cellular, immune responses.

Indexed as

Administration, IntranasalAnimalsAntibodies, ViralCholera ToxinImmunizationImmunoglobulin A, SecretoryImmunoglobulin GInterferon-gammaInterleukin-4SAIDS VaccinesSpodopteraT-Lymphocytes, CytotoxicVaccines, ConjugateVirionAntibodies, ViralCholera ToxinImmunoglobulin A, SecretoryImmunoglobulin GInterferon-gammaInterleukin-4SAIDS VaccinesVaccines, Conjugate

Identifiers

PMID12941891
PMCPMC224576
OpenAlexW2167693288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.